Polaris Group announced the submission of its new drug ADI-PEG 20 for the metabolic treatment of non-alcoholic steatohepatitis (NASH) for a randomised, double-blind, multi-centre Phase 2A clinical trial.

The clinical trial was designed as a randomized, double-blind, multicenter trial, with the primary assessment indicator being the absolute change in liver fat at baseline and at week 24 by MRI-PDFF. Observation of the inflammatory fractional system in NAFLD, etc.

The goal of treatment is to improve the inflammation and cirrhosis of NAFLD and to effectively control the symptoms associated with NAFLD, which may lead to severe cirrhosis, liver failure or liver cancer in about 25% of NAFLD patients.

In addition, NAFLD has a wide range of conditions, including type 2 diabetes, cardiovascular disease, chronic kidney disease, etc. Cardiovascular disease in particular is a major cause of death from NAFLD and is a significant health issue worldwide.

According to an analysis by Visiongain, an international market research centre, the market for non-alcoholic steatohepatitis is estimated to be US$17.3 billion in 2021 and is expected to reach US$62 billion in 2031, representing an annual compounded growth rate of 13.54%.